GDF-8 (Myostatin)
Myostatin (GDF-8), a TGF-beta-family protein that limits skeletal muscle growth; a research target for muscle-loss conditions.
Overview
Myostatin, officially growth/differentiation factor 8 (GDF-8), is an endogenous protein of the TGF-beta superfamily that acts as a negative regulator of skeletal muscle mass. It is not a small research peptide; interest in the peptide-research space centers on agents that block myostatin signaling to promote muscle growth. Loss-of-function mutations cause pronounced muscle hypertrophy in cattle breeds such as Belgian Blue, in dogs, and in rare human cases.
Mechanism
Myostatin is secreted as a precursor and processed into an active dimer that signals through activin type II receptors and SMAD transcription factors, restraining muscle fiber growth. Experimental inhibitors include antibodies, the myostatin propeptide, follistatin and related binding proteins, and soluble receptor decoys.
Expected Effects
- increased muscle mass reported in rodent studies of myostatin inhibition
- evaluation of myostatin blockade in muscle-wasting conditions and muscular dystrophy
- early human trial results have been mixed, with some effects on muscle mass but unclear functional benefit
Side Effects & Tolerability
Because the lead investigational agents are biologics rather than peptides, side-effect profiles are product-specific; one early receptor-decoy program was limited by tolerability findings in a small clinical trial. No myostatin inhibitor is approved for clinical use.
Storage
Myostatin is an endogenous protein and requires no storage guidance of its own; investigational inhibitor products should be handled according to their individual product documentation.